Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
5984 | 1547 | 41.8 | 84% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
0 | 4 | BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY | 4064930 |
275 | 3 | NSAIDS//CYCLOOXYGENASE//CYCLOOXYGENASE 2 | 43399 |
1311 | 2 | PROSTAGLANDIN D 2//CRTH2//MOL BEHAV BIOL | 8520 |
5984 | 1 | PROSTANOID RECEPTORS//EP3 RECEPTOR//IP RECEPTOR | 1547 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | PROSTANOID RECEPTORS | authKW | 481051 | 4% | 42% | 58 |
2 | EP3 RECEPTOR | authKW | 335126 | 2% | 57% | 30 |
3 | IP RECEPTOR | authKW | 325438 | 2% | 57% | 29 |
4 | EP4 RECEPTOR | authKW | 320179 | 2% | 43% | 38 |
5 | EP4 | authKW | 292470 | 2% | 44% | 34 |
6 | EP RECEPTORS | authKW | 270731 | 3% | 29% | 47 |
7 | PROSTACYCLIN RECEPTOR | authKW | 268139 | 2% | 54% | 25 |
8 | EP1 ANTAGONIST | authKW | 227548 | 1% | 82% | 14 |
9 | EP2 RECEPTOR | authKW | 209047 | 2% | 42% | 25 |
10 | ONO 1301 | authKW | 179423 | 1% | 91% | 10 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Pharmacology & Pharmacy | 2539 | 25% | 0% | 390 |
2 | Biochemistry & Molecular Biology | 1492 | 29% | 0% | 442 |
3 | Cell Biology | 1269 | 16% | 0% | 251 |
4 | Chemistry, Medicinal | 1167 | 9% | 0% | 136 |
5 | Immunology | 738 | 12% | 0% | 187 |
6 | Biophysics | 354 | 7% | 0% | 101 |
7 | Physiology | 332 | 6% | 0% | 93 |
8 | Chemistry, Organic | 250 | 7% | 0% | 114 |
9 | Medicine, Research & Experimental | 249 | 6% | 0% | 91 |
10 | Peripheral Vascular Diseases | 222 | 4% | 0% | 66 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | MINASE | 145603 | 3% | 18% | 42 |
2 | PHARMACEUT SCI PHYSIOL CHEM SAKYO KU | 44406 | 0% | 75% | 3 |
3 | FUKUI | 39784 | 1% | 18% | 11 |
4 | INVITRO PHARMACOL | 39473 | 0% | 100% | 2 |
5 | PHARMACOL ANGIOGENESIS | 39473 | 0% | 100% | 2 |
6 | HEADQUARTERS | 35769 | 1% | 10% | 19 |
7 | P PHARMACOL PHARMACOL TOXICOL SECT | 35083 | 0% | 44% | 4 |
8 | HERBERT | 26314 | 0% | 67% | 2 |
9 | PNEUMOL P ALLERGY | 24786 | 0% | 18% | 7 |
10 | UMR S698 | 24286 | 0% | 31% | 4 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | PROSTAGLANDINS & OTHER LIPID MEDIATORS | 33007 | 4% | 3% | 55 |
2 | BRITISH JOURNAL OF PHARMACOLOGY | 10602 | 6% | 1% | 98 |
3 | PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS | 5650 | 2% | 1% | 30 |
4 | BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 4670 | 5% | 0% | 78 |
5 | PROSTAGLANDINS | 4321 | 1% | 1% | 18 |
6 | AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY | 2485 | 2% | 0% | 29 |
7 | ADVANCES IN PROSTAGLANDIN THROMBOXANE AND LEUKOTRIENE RESEARCH | 2472 | 1% | 1% | 10 |
8 | JOURNAL OF LIPID MEDIATORS AND CELL SIGNALLING | 1771 | 0% | 2% | 5 |
9 | MOLECULAR PHARMACOLOGY | 1655 | 2% | 0% | 29 |
10 | EUROPEAN JOURNAL OF PHARMACOLOGY | 1546 | 3% | 0% | 48 |
Author Key Words |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | PROSTANOID RECEPTORS | 481051 | 4% | 42% | 58 | Search PROSTANOID+RECEPTORS | Search PROSTANOID+RECEPTORS |
2 | EP3 RECEPTOR | 335126 | 2% | 57% | 30 | Search EP3+RECEPTOR | Search EP3+RECEPTOR |
3 | IP RECEPTOR | 325438 | 2% | 57% | 29 | Search IP+RECEPTOR | Search IP+RECEPTOR |
4 | EP4 RECEPTOR | 320179 | 2% | 43% | 38 | Search EP4+RECEPTOR | Search EP4+RECEPTOR |
5 | EP4 | 292470 | 2% | 44% | 34 | Search EP4 | Search EP4 |
6 | EP RECEPTORS | 270731 | 3% | 29% | 47 | Search EP+RECEPTORS | Search EP+RECEPTORS |
7 | PROSTACYCLIN RECEPTOR | 268139 | 2% | 54% | 25 | Search PROSTACYCLIN+RECEPTOR | Search PROSTACYCLIN+RECEPTOR |
8 | EP1 ANTAGONIST | 227548 | 1% | 82% | 14 | Search EP1+ANTAGONIST | Search EP1+ANTAGONIST |
9 | EP2 RECEPTOR | 209047 | 2% | 42% | 25 | Search EP2+RECEPTOR | Search EP2+RECEPTOR |
10 | ONO 1301 | 179423 | 1% | 91% | 10 | Search ONO+1301 | Search ONO+1301 |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | WOODWARD, DF , JONES, RL , NARUMIYA, S , (2011) INTERNATIONAL UNION OF BASIC AND CLINICAL PHARMACOLOGY. LXXXIII: CLASSIFICATION OF PROSTANOID RECEPTORS, UPDATING 15 YEARS OF PROGRESS.PHARMACOLOGICAL REVIEWS. VOL. 63. ISSUE 3. P. 471 -538 | 292 | 32% | 146 |
2 | BREYER, RM , BAGDASSARIAN, CK , MYERS, SA , BREYER, MD , (2001) PROSTANOID RECEPTORS: SUBTYPES AND SIGNALING.ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY. VOL. 41. ISSUE . P. 661 -690 | 87 | 62% | 608 |
3 | KONYA, V , MARSCHE, G , SCHULIGOI, R , HEINEMANN, A , (2013) E-TYPE PROSTANOID RECEPTOR 4 (EP4) IN DISEASE AND THERAPY.PHARMACOLOGY & THERAPEUTICS. VOL. 138. ISSUE 3. P. 485-502 | 123 | 46% | 28 |
4 | MARKOVIC, T , JAKOPIN, Z , DOLENC, MS , MLINARIC-RASCAN, I , (2017) STRUCTURAL FEATURES OF SUBTYPE-SELECTIVE EP RECEPTOR MODULATORS.DRUG DISCOVERY TODAY. VOL. 22. ISSUE 1. P. 57 -71 | 76 | 78% | 0 |
5 | YOKOYAMA, U , IWATSUBO, K , UMEMURA, M , FUJITA, T , ISHIKAWA, Y , (2013) THE PROSTANOID EP4 RECEPTOR AND ITS SIGNALING PATHWAY.PHARMACOLOGICAL REVIEWS. VOL. 65. ISSUE 3. P. 1010-1052 | 161 | 32% | 31 |
6 | NARUMIYA, S , SUGIMOTO, Y , USHIKUBI, F , (1999) PROSTANOID RECEPTORS: STRUCTURES, PROPERTIES, AND FUNCTIONS.PHYSIOLOGICAL REVIEWS. VOL. 79. ISSUE 4. P. 1193 -1226 | 83 | 38% | 1593 |
7 | SUGIMOTO, Y , NARUMIYA, S , (2007) PROSTAGLANDIN E RECEPTORS.JOURNAL OF BIOLOGICAL CHEMISTRY. VOL. 282. ISSUE 16. P. 11613-11617 | 44 | 69% | 548 |
8 | HATA, AN , BREYER, RM , (2004) PHARMACOLOGY AND SIGNALING OF PROSTAGLANDIN RECEPTORS: MULTIPLE ROLES IN INFLAMMATION AND IMMUNE MODULATION.PHARMACOLOGY & THERAPEUTICS. VOL. 103. ISSUE 2. P. 147-166 | 82 | 38% | 426 |
9 | HIRATA, T , NARUMIYA, S , (2012) PROSTANOIDS AS REGULATORS OF INNATE AND ADAPTIVE IMMUNITY.ADVANCES IN IMMUNOLOGY, VOL 116. VOL. 116. ISSUE . P. 143-174 | 69 | 51% | 29 |
10 | HIRATA, T , NARUMIYA, S , (2011) PROSTANOID RECEPTORS.CHEMICAL REVIEWS. VOL. 111. ISSUE 10. P. 6209 -6230 | 91 | 40% | 27 |
Classes with closest relation at Level 1 |